Acalabrutinib

INN name:	Acalabrutinib
Lab codes:	ACP-196
Trade name:	Not yet marketed
Chemical name:	4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide
Molecular formula:	C26H23N7O2
Chemical Structure:
CAS Registry Number:	1420477-60-6
Originator:	Ascerta Pharma
Developer:	Acerta Pharma; Merck Sharp & Dohme
Class:	Antineoplastics
Mechanism of Action:	Agammaglobulinaemia tyrosine kinase inhibitors
WHO ATC code:	L01X-E (Protein kinase inhibitors) L04A (Immunosuppressants)
EPhMRA code:	L1H (Protein Kinase Inhibitor Antineoplastics) L4 (Immunosuppressants)
FDA approval:	Not yet approved
Clinical Trials: Indication Phase Status Chronic Lymphocytic Leukemia Phase 3 Recruiting Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL) Phase 1 Recruiting Carcinoma, Non-Small-Cell Lung Phase 2 Recruiting Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma Phase 2 Recruiting Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Prolymphocytic Leukemia Phase 1 Recruiting Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Richter's Syndrome|Prolymphocytic Leukemia Phase 1 Recruiting Follicular Lymphoma (FL) Phase 1 Recruiting Mantle Cell Lymphoma (MCL) Phase 2 Recruiting Metastatic Bladder Cancer Phase 2 Recruiting Metastatic Pancreatic Cancer Phase 2 Recruiting Multiple Myeloma (MM) Phase 1 Recruiting Non-hodgkin Lymphoma|Multiple Myeloma|B-All Phase 1|2 Recruiting Non-hodgkin Lymphoma|Multiple Myeloma|Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Richter's Syndrome|Waldenstrom Macroglobulinemia Phase 1|2 Recruiting Rheumatoid Arthritis Phase 2 Recruiting Squamous Cell Carcinoma of the Head and Neck Phase 2 Recruiting Waldenström Macroglobulinemia (WM) Phase 1 Recruiting
Product Patent Expiry: USA July 2032* (application under examination) South Korea July 2032* (application under examination) Canada July 2032* (application under examination) China July 2032* (application under examination) Japan July 2032* (application under examination) * The expiry date is based on the application filing, granted patent expiry may differ from the date mentioned. It is possible to extend the term of a patent in USA, KR and JP. The extension granted at the time of writing this post has been included and marked with **. Please leave a comment below for any update.
Recent activities on the drug: